Taysha Gene
TSHA

Taysha Gene (TSHA) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
Wolfe ResearchInitiated CoverageOutperform—Sep 17, 2026
Goldman SachsMaintainedBuy$13.00 from $11.00Jul 21, 2026
CitizensMaintainedMarket Outperform$11.00Jul 2, 2026
BairdMaintainedOutperform$15.00 from $12.00Jun 30, 2026
NeedhamMaintainedBuy$12.00Jun 30, 2026
B of A SecuritiesMaintainedBuy$10.00 from $9.00Jun 23, 2026
BMO CapitalMaintainedOutperform$14.00 from $10.00Jun 23, 2026
CitizensMaintainedMarket Outperform$11.00 from $8.00Jun 23, 2026
NeedhamMaintainedBuy$12.00Jun 22, 2026
Canaccord GenuityMaintainedBuy$17.00 from $14.00Apr 6, 2026
Chardan CapitalMaintainedBuy$12.00Mar 19, 2026
NeedhamMaintainedBuy$12.00 from $10.00Mar 19, 2026
NeedhamMaintainedBuy$10.00Mar 3, 2026
Chardan CapitalMaintainedBuy$12.00Jan 6, 2026
Wells FargoMaintainedOverweight$11.00 from $8.00Jan 5, 2026
Chardan CapitalMaintainedBuy$12.00Nov 5, 2025
CitizensMaintainedMarket Outperform$8.00 from $6.00Nov 5, 2025
Raymond JamesInitiated CoverageStrong Buy$13.00Oct 21, 2025
NeedhamMaintainedBuy$10.00Oct 17, 2025
Chardan CapitalMaintainedBuy$12.00Oct 17, 2025

Frequently asked questions

  • What is the latest analyst rating on TSHA?

    On Sep 17, 2026, Wolfe Research initiated coverage of Taysha Gene at Outperform.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.